Dabrafenib Plus Trametinib Approved for Pediatric BRAF V600E–Mutated Low-Grade Glioma

The FDA has granted approval to dabrafenib (Tafinlar®, Novartis) with trametinib (Mekinist®, Novartis) for treatment of pediatric patients with BRAF V600E–mutated low-grade glioma (LGG) who require systemic therapy. In addition, the FDA approved new oral formulations of dabrafenib and trametinib for patients who cannot swallow pills. This is notable as it is the first approval of a systemic therapy in a first-line setting for pediatric patients with BRAF V600E–mutated LGG. "LGG is the most commo...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.